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Abstract   123 
Our aim was to describe current approaches and to quantify variability between European intensive care 124 
units (ICU)s in patients with TBI. Therefore, we conducted a provider profiling survey as part of the 125 
‘Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury’ (CENTER-TBI) 126 
study. The ICU Questionnaire was sent to 68 centers from 20 countries across Europe and Israel. For this 127 
study, we used ICU questions focused on 1) hemoglobin target level (Hb-TL), 2) coagulation 128 
management, and 3) deep venous thromboembolism (DVT) prophylaxis. Seventy-eight participants, 129 
mostly intensivists and neurosurgeons of 66 centers completed the ICU questionnaire. For ICU-patients, 130 
half of the centers (N=34; 52%) had a defined Hb-TL in their protocol. For patients with TBI, 26 centers 131 
(41%) indicated a Hb-TL between 70 and 90 g/l and 38 centers (59%) above 90 g/l. To treat trauma 132 
related hemostatic abnormalities the use of fresh frozen plasma (N=48; 73%) or platelets (N=34; 52%) 133 
was most often reported, followed by the supplementation of vitamin K (N=26; 39%). Most centers 134 
reported using DVT prophylaxis with anticoagulants frequently or always (N=62; 94%). In the absence of 135 
hemorrhagic brain lesions, 14 centers (21%) delayed DVT prophylaxis until 72 hours after trauma. If 136 
hemorrhagic brain lesions were present, the number of centers delaying DVT prophylaxis for 72 hours 137 
increased to 29 (46%).  Overall, a lack of consensus exists between European ICUs on blood transfusion 138 
and coagulation management. The results provide a baseline for the CENTER-TBI study and the large 139 
between-center variation indicates multiple opportunities for comparative effectiveness research.         140 
 Keywords: intensive care unit; traumatic brain injury; coagulopathy; transfusion;  Europe  141 
 142 
143 
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Introduction 144 
 The management of hemorrhage and disordered coagulation is a common and critically 145 
important challenge in trauma patients.  This is particularly the case for patients with severe traumatic 146 
brain injury (TBI) where physicians have to balance the risks of progressive hemorrhage in the brain 147 
against secondary thrombotic complications including deep venous thrombosis (DVT). Many 148 
controversies continue to exist regarding the appropriate management for optimizing blood and 149 
coagulation status.  150 
 Transfusion thresholds for anaemia are a particularly controversial area in TBI. According to the 151 
guidelines 1, 2, transfusion in general critically ill patients is recommended at a restrictive hemoglobin 152 
target level (Hb-TL) of 70 g/l rather than a liberal Hb-TL of 90 g/l or 100g/l. Whether such target levels 153 
also apply to patients with TBI is unclear. 3, 4 Inappropriate use of blood products exposes patients to a 154 
number of systemic risks and may even lead to progressive hemorrhagic injury following TBI. 3 However, 155 
cerebral oxygenation may be improved with higher hemoglobin concentrations 5, 6 whereas restrictive 156 
transfusion thresholds may predispose to brain tissue hypoxia and may increase the risk of early 157 
mortality. 7 On the other hand, a recent large retrospective cohort study indicated that a restrictive 158 
blood transfusion policy was not associated with increased mortality and can be cost-effective in 159 
patients with TBI. 8 An additional challenge for the management of b th blood - and coagulation status 160 
is the presence of coagulopathy.9 Both pro- and anticoagulatory abnormalities can be observed after TBI 161 
in around one out of three patients. 10-12 Coagulopathy at admission is associated with increased 162 
mortality and poor neurological outcome. 12-14 Coagulopathy may result from defective clot initiation, 163 
poor clot formation or hyper fibrinolysis. Acidosis, hypothermia, coagulation factor consumption or 164 
dilution, and the more recently described acute coagulopathy of trauma-shock which results from 165 
widespread endothelial activation after hypoperfusion may contribute to coagulopathy. 15 Finally, 166 
patients with TBI are at increased risk of venous thromboembolism (VTE) (around 20%) 16 compared 167 
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with general ICU patients (around 6-8%). 17 Here, the balance between the prevention of VTE and the 168 
risk of (progressive) hemorrhage of the brain depends largely on the timing of thromboprophylaxis with 169 
anticoagulants. However, current Brain Trauma Foundation guidelines do not make clear 170 
recommendations on coagulation management. 18  171 
 In summary, no definitive evidence exists to guide physicians in determining the transfusion and 172 
coagulation management in patients with (severe) TBI. This will likely lead to variations in management. 173 
Our aim was to describe and quantify variability in European ICUs for blood transfusion and coagulation 174 
management in patients with TBI, using a survey among European neurotrauma centers participating in 175 
the Collaborative European Neurotrauma Effectiveness Research in TBI (CENTER-TBI) study. 19, 20 176 
 177 
  178 
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Material and Methods 179 
Participating centers 180 
 This study is part of the prospective, longitudinal ‘Collaborative European NeuroTrauma 181 
Effectiveness Research in Traumatic Brain Injury’ (CENTER-TBI) study in 68 centers from 20 countries 182 
across Europe and Israel. The CENTER-TBI investigators and participants are listed in Supplemental Data 183 
1. In 2014, before the start of inclusion of patients, the principle investigators of each center were asked 184 
to complete a set of questionnaires on structure and process of care: ‘the Provider Profiling 185 
Questionnaires’. 19, 20 The questionnaires were about TBI management irrespective of systemic injuries. 186 
One of these questionnaires concerned ICU management. 187 
 188 
Provider Profiling Questionnaire 189 
 The provider profiling questionnaire was developed in a systematic manner. The literature 190 
(including guidelines and available surveys) was reviewed and experts of various disciplines 191 
(neurosurgeons, (neuro)intensivists, neurologists, emergency department physicians, rehabilitation 192 
physicians, medical ethicists, health care economists and epidemiologists) were consulted throughout 193 
the different phases in the development process. Preliminary questionnaires were pilot-tested in 16 of 194 
the participating centers for unexpected or missing values and ambiguity, and received feedback was 195 
incorporated. For more information about the development, administration and content of the total set 196 
of provider profiling questionnaires, see Cnossen et al., 2016. 19 In this study, we focus on 10 questions 197 
(with additional sub questions) on hemoglobin target levels, trauma related coagulation management, 198 
and use and timing of thromboprophylaxis (Supplemental Data 2).   199 
    200 
Hemoglobin target level and coagulation management  201 
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 Participants were explicitly asked for their general policy rather than for individual treatment 202 
preferences. General policy was defined as ‘the way the large majority of patients (>75%) with a certain 203 
indication would be treated’. The ICU questionnaire consisted mostly of multiple-choice questions and 204 
one open question; the Hb-TL in the protocol at the ICU for the general ICU population. For the 205 
hemoglobin unit conversion from mmol/L towards g/L we multiplied with the factor 1.6 and then 206 
rounded up to tens.  207 
 208 
Statistical analysis 209 
 210 
 Descriptive statistics (frequencies and percentages) were used to describe the treatment 211 
policies reported by the participating centers. For some questions in which centers had to indicate how 212 
often a certain approach was taken by choosing ‘never’ (in 0-10% of cases), ‘rarely’ (in 10-30% of cases), 213 
‘sometimes’ (in 30-70% of cases), ‘frequently’ (in 70-90% of cases) and ‘always’ (90-100% of cases), 214 
categories were combined (e.g. combining ‘always’ and ‘frequently’) because of low numbers in these 215 
categories.  216 
 To gain more insight into characteristics that determine treatment policies we divided centers in 217 
relatively high- and middle-income countries versus lower-income countries, and in countries from 218 
different geographic locations (North and West Europe versus South and East Europe and Israel). The 219 
designation into relatively lower-income countries was based on a 2007 report by the European 220 
Commission 21, and the designation into geographic location was based on the classification by the 221 
United Nations. Analyses were performed using the Statistical Package for Social Sciences (SPSS) version 222 
21. 22 223 
  224 
 225 
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Results  226 
Participating centers 227 
 Sixty-six centers of the 68 centers completed the ICU questionnaire (response rate= 97%). The 228 
questionnaire was completed by intensivists (N=33; 50%), neurosurgeons (N=23; 35%), administrative 229 
staff (N=11; 17%), neurologists (N=5, 8%), anesthetists (N=5, 8%) and a trauma surgeon (N=1; 2%). 230 
Almost all the centers had an academic affiliation (N=60; 91%) and most centers were designated as a 231 
level I trauma center (N=44; 67%). Centers had a median of 33 (interquartile range 22-44) beds for 232 
general ICU patients and treated a median of 92 (interquartile range 52-160) patients with TBI, of all 233 
severities, annually. An extensive overview of all the center characteristics is described in a previous 234 
publication. 19  235 
 For the management of TBI at the ICU, most centers indicated to follow the 2007 Brain Trauma 236 
Foundation (BTF) guidelines (N=28; 42%) or institutional guidelines (N=21; 32%), which were broadly 237 
based on BTF and/or national guidelines. Some centers indicated they did not have specific guidelines 238 
for management of TBI (N=11; 17%) or that they developed a guideline independently from available 239 
guidelines (N=2; 3%).   240 
Hemoglobin target level 241 
 Half of the centers (N=34; 52%) reported to have hemoglobin target levels (Hb-TL) described in 242 
their protocol for general/non-TBI ICU patients. The reported Hb-TL varied (open question): 110 g/l 243 
(N=1; 3%), 100 g/L (N=8; 28%), 90 g/L (N=4; 14%), 80 g/L (N=9; 31%), 70 g/L (N=5; 18%), 80-100 g/L (N=1; 244 
3%) and 70-80 g/L (N=1, 3%). In non-neurological critically ill patients, 35 of the centers (56%) reported a 245 
Hb-TL between 70 g/L and 80 g/L. In patient with TBI, 10 of the centers (16%) indicated to use a Hb-TL 246 
between 70 and 80 g/L. The remainder of the centers used higher Hb-TL: between 80 g/L and 90 g/L (N= 247 
16; 25%), between 90g/L and 100 g/L (N=20; 31%), and above 100 g/L (N=18; 28%). (Table 1) 248 
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[Insert HuijbenTable1] 249 
Coagulation management 250 
 Transfusion with fresh frozen plasma was most often reported for correction of trauma related 251 
coagulopathy (N= 48; 73%), followed by the use of platelets (N=34; 52%).  Coagulopathy was most often 252 
managed with vitamin K (N=26; 39%), fibrinogen (N=19; 29%), Prothrombin Complex Concentrate (N= 253 
17; 26%), Tranexamic acid (N=7; 11%) or recombinant factor VIIa (N=3; 5%). One center reported to use 254 
Desmopressin, in addition to Tranexamic Acid. (Figure 1) 255 
[Insert HuijbenFig 1] 256 
 Most centers indicated that they use deep venous thrombosis (DVT) prophylaxis with 257 
anticoagulants frequently (N=18; 27%) or always (N=44; 67%) in patients with TBI. Fourteen centers 258 
(21%) indicated they generally wait 72 hours after trauma before commencing DVT prophylaxis in the 259 
absence of hemorrhagic brain lesions. However, twice that number of centers (N=29; 46%) indicated to 260 
wait 72 hours after trauma in the presence of hemorrhagic brain lesions. Low molecular weight heparin 261 
was most commonly indicated as the prophylactic drug of choice (N=54; 82%), followed by 262 
subcutaneous unfractioned heparin (N=7; 11%) and intravenous heparin (N=1; 2%).  (Table 2)  263 
[Insert HuijbenTable2]  264 
 Most centers indicated that they would always test a coagulation panel prior to the insertion of 265 
a parenchymal sensor (N=45; 69%) or a ventricular catheter (N=46; 71%). The reported minimum 266 
platelet count for the insertion of a ventricular catheter was variable: >100 x109/L (N=30; 46%), >80 267 
x109/L (N=9; 14%) or >50 x109/L (N=9; 14%). In most of the remaining centers the minimum platelet 268 
count depended on the surgeon (N=13; 20%). Also, the reported minimum International Normalized 269 
Ratio (INR) considered safe for placement of a ventricular catheter was variable: <1.4 (N=21; 33%), <1.3 270 
(N=17; 26%) or <1.2 (N=8; 12%). Again, in most of the remaining centers the minimum INR was indicated 271 
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to depend on surgeon’s individual preferences (N=15; 23%).  There were no centers that answered 272 
‘never’ on all questions. (Table 3)  273 
[Insert HuijbenTable3] 274 
 Twenty-nine centers indicated identical policies for coagulation management (always using DVT 275 
prophylaxis, and always obtaining a coagulation panel prior to insertion of a parenchymal or ventricular 276 
catheter). The majority of these centers are located in South and East Europe and Israel (N=13, 56%) 277 
versus (N=16, 37%) in North and West Europe and the majority are located in high income countries 278 
(N=26, 47%), versus (N=3, 27%) in lower income countries.  279 
 280 
 281 
 282 
 283 
 284 
 285 
 286 
 287 
 288 
 289 
 290 
291 
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Discussion  292 
 This study shows large between-center variation in blood transfusion and coagulation-directed 293 
policies in critically ill patients with TBI. More centers indicated a restrictive Hb-TL (between 70 g/l and 294 
80 g/L) in general ICU patients compared to patients with TBI. Reported coagulation management was 295 
variable regarding timing of deep venous thrombosis (DVT) prophylaxis with anticoagulants, minimum 296 
platelet count and INR values prior to ICP probe insertion, and correction of trauma related 297 
coagulopathy.   298 
  The large between-center differences are likely in part explained by a lack of evidence on 299 
optimal management of patients with TBI. A majority of centers in our study reported to adhere to the 300 
2007 Brain Trauma Foundation (BTF) guidelines for the treatment of patients with TBI, but this guideline 301 
does not provide specific recommendations on red blood cell transfusion or coagulopathy management. 302 
Equally, some trauma guidelines have stated policies on blood transfusion and coagulation in trauma 303 
patients of which some pertain to patients with TBI, but recommendations are still scarce. 1, 2, 23 A recent 304 
update of the Cochrane Review of all Red Cell Transfusion trials reported on 12587 patients identified in 305 
31 randomized trials and suggested that a restrictive rather than liberal transfusion practice improves 306 
outcomes, but noted the data was very limited for neurocritical care.24  Regarding patients with TBI, 307 
several trials have been conducted on blood transfusion management 25, 26, and the reversal of 308 
coagulopathy 27, 28, but these all had a limited power. A recent large retrospective single-center study in 309 
TBI patients admitted to the intensive care 8 found that transfusion guided by a restrictive Hb-TL was 310 
associated with significantly less time with fever, higher cost-effectiveness and had the same risk of 311 
mortality compared with a liberal Hb-TL. Another explanation for the variation in management would be 312 
the between-center variation in the content of available protocols. E.g. we found that even between 313 
centers that do have a protocol on red blood cell transfusion policy, the reported Hb-TL still varied 314 
substantially. Overall in patients with TBI, there is no conclusive evidence or clear guidance in guidelines 315 
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and protocols on blood transfusion and coagulopathy treatment. Still, with an aging TBI demographic 316 
with an increased prevalence of comorbidity, coagulation management might even become more 317 
complex. Concurrent use of anticoagulant and antiplatelet medication is a growing concern, prior 318 
warfarin treatment for example is associated with an increased risk of poor outcome. 29 In addition, 319 
coagulation management in TBI is further complicated by the recent introduction of newer 320 
anticoagulants, such as direct thrombin inhibitors (dabigatran, argatroban).30   321 
 322 
 For DVT prophylaxis the BTF guidelines do provide a recommendation, which was formulated 323 
quite broadly: DVT prophylaxis with anticoagulants can be started if the brain injury is stable and the 324 
benefit is considered to outweigh the risk of increased intracranial hemorrhage. Recommendations on 325 
the preferred agent, dose, or timing are lacking. 18 In our study only 65% of centers indicated that they 326 
always would implement DVT prophylaxis. A review including 15 studies and 4,491 patients on DVT 327 
occurrence in TBI published in 2015 showed that DVT incidence is significantly increased (18% versus 328 
approximately 2%) when pharmaceutical prophylaxis is not given in the first 8 days.31 For the timing 329 
issue in DVT prophylaxis a novel theoretical prophylaxis protocol, ‘the Parkland Protocol’ has been 330 
recently described.32 The protocol takes into account the likelihood of natural progression of brain 331 
hemorrhage and in that way determines the timing of anticoagulation. The risk classification is based on 332 
the stability of the brain hemorrhage at a computed tomography (CT) scan, the modified Berne 333 
Norwood criteria (subdural hematoma >8 mm, epidural hematoma >8 mm, contusion or intraventricular 334 
hemorrhage >2 cm, multiple contusions per lobe, subarachnoid hemorrhage with abnormal CT 335 
angiography), and the presence of an ICP monitor or craniectomy. A randomized controlled trial (RCT) 336 
including 62 low risk patients showed the safety of this protocol for this group: no progression of brain 337 
hemorrhage with the use of low molecular weight heparin at 24 hours post injury and one DVT with the 338 
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use of placebo at 24 hours post injury. 33 However, more evidence is needed before this protocol can be 339 
widely accepted for the guidelines.  340 
 The large between center-variation we found is in line with previous studies. For critically ill 341 
trauma patients, several surveys have been conducted to study the management of trauma related 342 
hemorrhage and coagulopathy. 34-36 These studies also found large differences in clinical practices, even 343 
among level 1 trauma centers, for example in the use of viscoelastic testing. In the survey of Hamada et 344 
al. the reported Hb-TLs in critically ill trauma patients were compared with patients with TBI, and were 345 
significantly higher in pati nts with TBI, like in our study.37 In addition, two previous surveys were 346 
conducted that report the percentage respondents that chose specific Hb-TLs and the rationale for 347 
blood transfusion in patients with TBI (coagulation management was not assessed). In the study of Sena 348 
et al. a newly developed multiple-choice survey was completed by 312 physicians of the trauma surgery 349 
-, neurosurgery -, and ICU department of level I trauma centers in the United States.38  In the study of 350 
Badenes et al. a newly developed multiple-choice survey was used as well, but was completed by 868 351 
respondents, mostly specialists in anesthesiology and intensive care, worldwide.39 In the study of Sena 352 
et al. 55% of respondents chose a restrictive policy of 70 g/l or less. Likewise, in the study of Badenes et 353 
al. 50% of respondents chose a low Hb-TL of 70 or 80 g/l, while in our study 16% chose a Hb-TL between 354 
70 and 80 g/. The difference could either be explained by a difference in patient population (severely 355 
injured patients with TBI in the study of Sena et al.), by a difference in answer options (we did not have 356 
an answer option below 70 g/l), or by a difference in policy between Europe and other continents.  357 
 Strengths of our study include the comprehensive development process of the questionnaires 358 
and the high response rate of 97%. Limitations include the survey-design, resulting in perceived 359 
practices rather than actual practices. Although we explicitly asked for general policy and data were 360 
anonymously collected, we cannot exclude differences between current findings and actual treatment in 361 
the participating centers. In addition, questions were aimed to assess general policy and contained no 362 
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specific details on patient characteristics. This is not representative for clinical practice (possibly making 363 
the questions more difficult to answer). In addition, we could not make a distinction between 364 
pharmaceutical versus mechanical DVT prophylaxis. A further limitation comprises the 365 
representativeness of our sample. The majority of centers were Academic level I trauma centers with a 366 
special interest in neurotrauma. Findings are therefore not generalizable to non-specialized centers. In 367 
addition, differences between centers could represent differences in case-mix instead of true practice.  368 
 The practice variability we report supports that evidence on optimal treatment approaches is 369 
needed. Such evidence can potentially be obtained in a non-randomized design by comparing outcomes 370 
between centers with different treatment policies. Such a Comparative Effectiveness Research approach 371 
exploits the existing between-center variation. Data on real time patient management and clinically 372 
relevant outcomes in the CENTER-TBI study are now being collected.20 Future research on blood 373 
transfusion and coagulation management in patients with TBI could lead to prevention of progressive 374 
brain hemorrhage and secondary problems like coagulopathy and VTE. For now, the optimal transfusion 375 
strategies to correct coagulopathy in terms of the ratio of packed blood cells, fresh frozen plasma (or 376 
similar products) and platelets are still being debated. 40 This debate pertains both to optimal strategies 377 
with regard to reversal of trauma related coagulopathy and management of coagulopathy induced by 378 
conventional agents (such as vitamin K antagonists) and newer ones such as direct thrombin inhibitors. 9, 379 
30, 41 Still, others warn for the use of transfusion considering the possibility of complications of 380 
transfusion and unknown effects on (functional) outcome.42 Also for coagulation (enhancing) products 381 
larger studies are needed to prove a positive balance between the beneficial effects in terms of patient 382 
outcome and adverse effects on (thromboembolic) complications.27, 28, 42-45 New evidence is clearly 383 
needed on these topics, since control of blood and coagulation status could have a large impact on 384 
patient outcome, especially in patients with TBI. 385 
 386 
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Conclusions 387 
 In conclusion, we showed substantial variation in blood and coagulation management of 388 
patients with TBI at the ICUs in 66 centers in Europe and Israel participating in the CENTER-TBI study. 389 
This variation may be largely attributable to the lack of guidelines and high quality evidence on these 390 
topics. The large practice variation provides an opportunity to study the effectiveness of different 391 
policies in comparative effectiveness research.  392 
  393 
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 Table 1. Red blood cell transfusion policy a   
Items  
questionnaire  
Number 
completed 
N                 (%) 
Protocol at the ICU   
Protocol 
- Presence of a protocol with a Hb-TL 
- Absence of a protocol with a Hb-TL 
65 
 
 
34 
31 
  
(52%) 
(48%) 
Transfusion at Hb-TL in protocol (open question)   
- 110 g/L 
- 100g/L 
- 90 g/L 
- 80 g/L 
- 70 g/L 
- 80-100 g/L 
- 70-80 g/L 
29  
 
 
1    
8    
4   
9 
5 
1 
1 
 
(3%) 
(28%) 
(14%) 
(31%) 
(18%) 
(3%) 
(3%) 
In non-neurological critically ill  patients   
Transfusion at Hb-TL 
- > 100 g/L  
- Between 90 g/l and 100g/L 
- Between 80 g/l and 90 g/L 
- Between 70 g/l and 80 g/L 
63  
1    
6  
21 
35 
 
(2%) 
(9%) 
(33%) 
(56%) 
In patients with TBI b   
Transfusion at Hb-TL 
- > 100 g/L 
- Between 90 g/l and 100g/L 
- Between 80 g/l and 90 g/L 
- Between 70 g/l and 80 g/L 
64  
18  
20  
16 
10 
 
(28%) 
(31%) 
(25%) 
(16%) 
Frequencies and percentage of centers with corresponding answers, ICU: Intensive Care Unit, Hb-TL: hemoglobin 
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target levels, TBI: traumatic brain injury, g/L: grams per liter 
a) General policy: the way the large majority of patients (>75%) with a certain indication would be treated at the 
intensive care b) Policy in the acute phase 
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Table 2. Coagulation policies, deep venous thrombosis a  
Items  
questionnaire 
Number 
completed 
N                (%) 
DVT prophylaxis   
Frequency of DVT prophylaxis  
- Never  (0-10%) 
- Rarely   (10-30%) 
- Sometimes  (30-70%) 
- Frequently  (70-90%) 
- Always   (90-100%) 
66 
  
 
 
1    
0  
3    
18 
44  
 
(2%) 
(0%) 
(4%) 
(27%) 
(67%) 
Start in the absence of hemorrhagic lesions  
- < 24 hours 
- 24-72 hours 
- > 72 hours 
- Never 
Start in the presence of hemorrhagic lesions 
- < 24 hours 
- 24-72 hours 
- > 72 hours 
- Never 
Start after intracranial surgery 
- < 24 hours 
- 24-72 hours 
- > 72 hours 
- Never 
65 
 
 
 
 
63 
 
 
 
 
64 
 
 
 
26 
24 
14 
1 
 
5 
25 
29 
4 
 
10 
31 
21 
2 
 
(40%) 
(37%) 
(21%) 
(2%) 
 
(8%) 
(40%) 
(46%) 
(6%) 
 
(16%) 
(48%) 
(33%) 
(3%) 
Pharmacological DVT prophylaxis 
- Subcutaneous unfractioned heparin 
- Intravenous heparin 
66  
7 
1 
(11%) 
(2%) 
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- Low-molecular weight heparin 54 (82%) 
Frequencies and percentage of centers with corresponding answers  
DVT: deep venous thrombosis 
a) General policy: the way the large majority of patients >75% with a certain indication would be treated at the 
intensive care  
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Table 3. Coagulation policies, ICP monitoring a   
Items  
questionnaire 
Number 
completed 
N                        (%) 
 
Checks prior to insertion of parenchymal sensor for ICP monitoring  
Coagulation panel  
- Never  (0-10%) 
- Rarely   (10-30%) 
- Sometimes  (30-70%) 
- Frequently  (70-90%) 
- Always   (90-100%) 
- Not available b 
65  
4 
2 
5 
5 
45 
4 
 
(6%) 
(3%) 
(8%) 
(8%) 
(69%) 
(6%) 
Checks prior to insertion ventricular catheter for ICP monitoring   
Coagulation panel 
- Never  (0-10%) 
- Rarely   (10-30%) 
- Sometimes  (30-70%) 
- Frequently  (70-90%) 
- Always   (90-100%) 
- Not available b 
Minimum platelet count 
- >150 x109/L 
- >100 x109/L 
- > 80 x109/L 
- > 50 x109/L 
- Depending on the surgeon 
- No minimum  
- Other 
Minimum INR  
65 
 
 
 
 
 
 
65 
 
 
 
 
 
 
 
65 
 
3 
2 
5 
4 
46 
5 
 
1 
30 
9 
9 
13 
0 
3 
 
 
(4%) 
(3%) 
(8%) 
(6%) 
(71%) 
(8%) 
 
(2%) 
(46%) 
(14%) 
(14%) 
(20%) 
(0%) 
(4%) 
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- <1.4  
- <1.3  
- <1.2  
- Depending on the surgeon 
- No minimum 
- Other 
21 
17 
8 
15 
0 
4 
(33%) 
(26%) 
(12%) 
(23%) 
(0%) 
(6%) 
Frequencies and percentage of centers with corresponding answers  
DVT: deep venous thrombosis, ICP: intracranial pressure, INR: International Normalized Ratio, L: Liter 
a) General policy: the way the large majority of patients >75% with a certain indication would be treated at the 
intensive care b) Centers that did not have this technique 
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Figure 1. Trauma related coagulopathy treatment  
 
297x420mm (300 x 300 DPI)  
 
 
Page 36 of 55
Mary Ann Liebert, Inc, 140 Huguenot Street, New Rochelle, NY 10801
Journal of Neurotrauma
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only/Not for Distribution
Figure title 
Figure 1. Trauma related coagulopathy treatment  
Figure legend 
Bars represent the percentage of centers that indicated to use this treatment as general policy (the way the 
large majority of patients >75% with a certain indication would be treated). In order of always and frequently 
summed. Always: in 90-100% of cases; Frequently: in 70-90% of cases; Sometimes: in 30-70% of cases; Rarely: 
in 10-30% of cases; Never: in 0-10% of cases  
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Supplemental data 2. Provider Profiling Questionnaire (ICU part) 
 
The following questions about ICU policies are included in the manuscript 
 
Information about the completer of the questionnaire 
Other than the CENTER-TBI investigator, which of the following individuals was involved in completion of 
this questionnaire? 
Select all that apply 
  Neurologist 
  Neurosurgeon 
  Trauma Surgeon 
  ED physician 
  Administrative staff member / data manager / financial department 
  Other, please specify…………….. 
  NA. The questionnaire is solely completed by the CENTER TBI local investigator 
The Local investigator is the senior clinician(s) at your hospital involved in supervision of CENTER TBI 
 
General patient statistics 
What is the number of patients treated in your Intensive Care Unit (ICU) annually?  
1. 2012: …………………………………….. 
2. 2013: …………………………………….. 
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What is the number of Traumatic Brain Injury (TBI) patients treated in your Intensive Care Unit (ICU)  
annually? 
3. 2012: …………………………………….. 
4. 2013: …………………………………….. 
 
With reference to guidelines for Intensive Care Unit (ICU)  management of Traumatic Brain Injury (TBI), 
does your ICU: 
o Not have specific guidelines for management 
o Follow the Brain Trauma Foundation Guidelines 
o Follow National Guidelines (Please specify:  ………………………………………………) 
o Have institutional guidelines which are broadly based on BTF and/or National Guidelines 
o Have separate guidelines which you have developed independently 
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Intensive Care Unit (ICU)  practice around ICP monitoring 
 Never (0-
10%) 
Rarely (10-
30%) 
Sometimes 
(30-70%) 
Frequently 
(70-90%) 
Always (90-
100%) 
N/A, we 
do not 
have this 
technique 
   
23. Is a 
coagulation 
panel 
assessed 
prior to 
insertion of 
an ICP 
monitoring 
device? 
 
Ventricular catheter: 
o  o  o  o  o  o  
Parenchymal sensor 
o  o  o  o  o  o  
24. What is considered a minimum platelet count for insertion of a ventricular catheter in your Intensive 
Care Unit (ICU)? 
o >150K 
o >100K 
o > 80 K 
o >50K 
o Variable, depends on surgeon 
o No minimum 
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o Other, please specify ……………………………………. 
 
25. What is consider the minimum INR for safe placement of a ventricular catheter in your Intensive 
Care Unit (ICU)? 
o <1.4 
o <1.3 
o <1.2 
o Variable, depending on surgeon 
o No minimum 
o Other, please specify……………………………………………………………….. 
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Deep venous thrombosis (DVT) prophylaxis 
The responses to the following questions should represent, as best as practicable, a general consensus on treatment at your 
centre, rather than individual management preferences.   
 Never (0-10%) Rarely (10-
30%) 
Sometimes 
(30-70%) 
Frequently 
(70-90%) 
Always (90-
100%) 
 
53. How often is 
DVT prophylaxis 
used? 
 
               
 
54. If you use DVT prophylaxis, when is DVT prophylaxis initiated? 
 < 24 hrs 24-72 hrs < 72 hrs Never 
In the absence of 
hemorrhagic lesions 
 
            
In the presence of 
hemorrhagic lesion 
 
            
After intracranial surgery 
 
 
            
55. In patients who receive DVT prophylaxis, what medication is given? 
  Subcutaneous unfractioned heparin 
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  Low-molecular weight heparin 
  Other, please specify……………………………………………………………………… 
 
 
56. Coagulopathy related to the trauma is treated with : 
 
 Never (0-10%) Rarely (10-
30%) 
Sometimes 
(30-70%) 
Frequently 
(70-90%) 
Always (90-
100%) 
Fresh Frozen 
plasma (FFP) 
 
               
Platelets 
 
               
Fibrinogen 
 
 
               
Novo 7 ( 
recombinant factor 
VII) 
               
Vitamin K                
PCC (Prothrombin 
Complex 
Concentrate) 
               
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